NV Energy (NYSE: NVE ) � is a selection for the real-money Inflation-Protected Income Growth portfolio. Like any investment, it needs to be reviewed from time to time to see if it's still worth owning. In the brief video below, portfolio manager Chuck Saletta reviews its valuation, balance sheet, and dividends, and decides whether to hold on to the stock or let it go.
To follow the iPIG portfolio as buy and sell decisions are made, watch Chuck's article feed by clicking here. To join The Motley Fool's free discussion board dedicated to the iPIG portfolio, simply click here.
Will Exelon's troubles soon be over?
As the nation moves increasingly toward clean energy, Exelon is perfectly positioned to capitalize on having the largest nuclear fleet in North America. This strength, combined with an increased focus on balance sheet health and its recent merger with Constellation, places Exelon and its resized dividend on a short list of the top utilities. To determine if Exelon is a good long-term fit for your portfolio, you're invited to check out The Motley Fool's premium research report on the company. Simply click here now for instant access.
10 Best Low Price Stocks To Invest In Right Now: Dynavax Technologies Corporation(DVAX)
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The company's lead product candidate includes HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide protection with fewer doses than current licensed vaccines. It also develops Universal Flu vaccine, a Phase 1b clinical trial vaccine for influenza prevention; SD-101, a Phase Ib clinical trial hepatitis C therapy; DV-601, a Phase Ib clinical trial hepatitis B therapy; AZD1419, a preclinical asthma therapy; and DV1179, a Phase 1 trial autoimmune and inflammatory disease therapy. Dynavax Technologies Corporation has strategic alliance with GlaxoSmithKline plc to discover, develop, and commercialize DV1179 and other endosomal toll-like receptor inhibitors for diseases, such as lupus, psoriasis, and rheumatoid arthritis; and develop a TLR8 inhibitor for the treatment of multiple autoimmune and i nflammatory diseases, as well as has research and license agreement with AstraZeneca to discover and develop TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was founded in 1996 and is based in Berkeley, California.
Advisors' Opinion:- [By Keith Speights]
Dynavax (NASDAQ: DVAX ) is a good case in point. The company's Heplisav hepatitis B vaccine looked good in clinical trials when compared to the leading vaccine on the market. Dynavax thought that the safety profile for Heplisav also compared favorably. The Food and Drug Administration even told the company that it could expand its Biologic License Application, or BLA, to include a wider age range of adults than originally planned.
- [By Roberto Pedone]
Another under-$10 bio therapeutic player that's starting to trend within range of triggering a major breakout trade is Dynavax Technologies (DVAX), which discovers and develops novel products to prevent and treat infectious and inflammatory diseases. This stock has been hit hard by the sellers so far in 2013, with shares off sharply by 55%.
If you take a look at the chart for Dynavax Technologies, you'll notice that this stock has been trending inside of a big range for the last three months and change, with shares moving between $1.10 on the downside and $1.46 on the upside. This large consolidation pattern for DVAX could mean that this stock is under accumulation by the bulls, since the bears have been unable to push the stock out of this range and take it to new lows. Shares of DVAX are now starting to spike back above its 50-day moving average of $1.25 a share with decent upside volume. Volume so far on Thursday has already registered 1.6 million shares versus its three-month average action or 1.81 million shares. This move is starting to push DVAX within range of triggering a major breakout trade.
Market players should now look for long-biased trades in DVAX if it manages to break out above some key overhead resistance levels at $1.29 to $1.32 a share, and then once it takes out more resistance at $1.46 to $1.50 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 1.81 million shares. If that breakout hits soon, then DVAX will set up to re-test or possibly take out its next major overhead resistance level at $1.70 a share. Any high-volume move above $1.70 a share will then give DVAX a chance to re-fill some of its previous gap down zone from June that started at $2.60 a share.
Traders can look to buy DVAX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.10 a sha
- [By Keith Speights]
Of course, developing a product for a market with great opportunity doesn't guarantee success for your investment strategy. An estimated 1 million people die each year from complications related to hepatitis B. Dynavax (NASDAQ: DVAX ) developed a hep-B vaccine, Heplisav, that showed tremendous promise. However, safety concerns derailed approval for the drug. While Heplisav might still reach the market, Dynavax's experience highlights the risks even in a market with solid potential.
- [By Holly LaFon]
Steven Cohen, George Soros and John Paulson are three of the most formidable investors alive today. All three of them added to one of their major holdings so far in 2012. Steven Cohen of SAC Capital Advisors added Dynavax Tech Cp (DVAX), George Soros of Soros Fund Management LLC added Acacia Research (ACTG) and John Paulson of Paulson & Co. added Novagold Resources (NG).
Top 5 Clean Energy Companies To Own In Right Now: Newcrest Mining Ltd (NCM)
Newcrest Mining Limited (Newcrest) is a gold, copper and silver producer that has operations and exploration projects in Australia, the Pacific region, Asia and West Africa. The Company�� segments include Cadia Valley, Telfer, Gosowong, Lihir, Hidden Valley JV, West Africa (includes Bonikro operations and exploration and evaluation activities in Cote d��voire) and Exploration and Other. Exploration and Other mainly consists of projects in the exploration, evaluation and feasibility phase and includes Namosi in Fiji, Wafi Golpu in Papua New Guinea (PNG), and Marsden and O��allaghans in Australia. Cadia Valley Operations (CVO) is a gold mining operation and is 100% owned by Newcrest. It is located approximately 25 kilometers from the city of Orange in central west New South Wales and is 250 kilometers west of Sydney. Advisors' Opinion:- [By Jasmine Ng]
Newcrest Mining Ltd. (NCM), Australia�� biggest gold producer, sank 6.7 percent as bullion traded near a five-month low. Hyundai Motor Co., South Korea�� top carmaker, lost 4.2 percent as November sales fell. Sekisui Chemical Co. surged 7.5 percent in Tokyo on a report it developed a material that triples the capacity of electric-vehicle batteries.
- [By Holly LaFon]
The Fund's top detractors were Gold bullion, Newcrest Mining (NCM), Goldcorp (GG), Penn West Petroleum and Fresnillo PLC (FRES). Newcrest, Goldcorp and Fresnillo all suffered along with other gold miners as a result of the decline in the gold price during the year. Bangkok Bank (BKK:BBL)'s performance reflected the decline in the Thai SET Index which fell 11% during the quarter in dollar terms as a result of political issues in Thailand.
- [By Jonathan Burgos]
Raw-material producers advanced. Rio Tinto climbed 4.3 percent to A$54.32 in Sydney. Newcrest Mining Ltd. (NCM), Australia�� biggest gold producer, rose 4.8 percent to A$16.65, paring its biggest weekly loss since October 2008. BHP Billiton Ltd., the world�� largest mining company, gained 2.5 percent to A$31.40.
Top 5 Clean Energy Companies To Own In Right Now: Athersys Inc.(ATHX)
Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its clinical development programs are focused on treating cardiovascular disease, neurological conditions, inflammatory and immune disorders, and other conditions. Its product pipeline includes MultiStem, a novel allogeneic approach to stem cell therapy and regenerative medicine for treating a range of diseases. The company is also involved in the development of novel small molecule compounds for applications in indications, such as obesity and other areas, including the treatment of neurological conditions, and for the modulation of stem cells or related applications in the regenerative medicine area. It has product co-development collaboration with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease for the worldwide market; Angiotech Pharmaceuticals, Inc. to develop and commerciali ze MultiStem to treat certain cardiovascular diseases, such as acute myocardial infarction; and RTI Biologics, Inc. to develop and commercialize biologic implants for certain orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
Advisors' Opinion:- [By GuruFocus]
George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated
- [By Roberto Pedone]
Athersys (ATHX), a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. This stock closed up 2.5% to $1.59 in Thursday's trading session.
Thursday's Range: $1.53-$1.59
52-Week Range: $1.08-$4.33
Thursday's Volume: 128,000
Three-Month Average Volume: 416,142From a technical perspective, ATHX bounced notably higher here right above some near-term support levels at $1.53 to $1.49 with lighter-than-average volume. This stock has been trending sideways and consolidating for the last two months, with shares moving between $1.49 on the downside and $1.99 on the upside. This spike higher on Thursday is starting to push shares of ATHX within range of triggering a near-term breakout trade. That trade will hit if ATHX manages to take out Thursday's intraday high of $1.59 to its 50-day moving average of $1.65 with high volume.
Traders should now look for long-biased trades in ATHX as long as it's trending above some key near-term support at $1.49 and then once it sustains a move or close above those breakout levels with volume that hits near or above 416,142 shares. If that breakout kicks off soon, then ATHX will set up to re-test or possibly take out its next major overhead resistance levels at $1.70 to $1.73, or even $1.78. Any high-volume move above $1.78 will then give ATHX a chance to re-test or possibly take out the upper-end of its recent range at $1.99.
- [By Roberto Pedone]
Athersys (ATHX) is a biopharmaceutical company focused in the field of regenerative medicine. This stock closed up 4% to $1.79 in Thursday's trading session.
Thursday's Range: $1.68-$1.80
52-Week Range: $0.95-$2.42
Thursday's Volume: 270,000
Three-Month Average Volume: 323,188From a technical perspective, ATHX bounced notably higher here right off its 50-day moving average of $1.67 with decent upside volume. This stock recently pulled back from $1.99 to its 50-day at $1.67. Shares of ATHX may now be down with that pullback, since the stock is starting to trend higher and move within range of triggering a near-term breakout trade. That trade will hit if ATHX manages to take out some near-term overhead resistance levels at $1.90 to $1.99 with high volume.
Traders should now look for long-biased trades in ATHX as long as it's trending above its 50-day at $1.67 and then once it sustains a move or close above those breakout levels with volume that hits near or above 323,188 shares. If that breakout triggers soon, then ATHX will set up to re-test or possibly take out its next major overhead resistance levels at $2.16 to $2.25. Any high-volume move above those levels will put its 52-week high at $2.42 into range for shares of ATHX.
Top 5 Clean Energy Companies To Own In Right Now: WESCO International Inc. (WCC)
WESCO International, Inc. engages in the distribution of electrical, industrial, and communications maintenance, repair, and operating (MRO) products; and original equipment manufacturers products and construction materials. It also provides supply chain management and logistics services. The company offers general and industrial supplies, such as wiring devices, fuses, terminals, connectors, boxes, enclosures, fittings, lugs, terminations, tapes, splicing and marking equipment, tools and testers, safety and security, personal protection, abrasives, cutting tools, consumables, fasteners, janitorial, and other MRO supplies. It also provides wires, cables, raceway, and metallic and non-metallic conduits; and communications products, such as structured cabling systems, broadband products, low voltage specialty systems, specialty wire and cable products, equipment racks and cabinets, access controls, alarms, cameras, and paging and voice solutions. In addition, the company off ers power distribution equipment, such as circuit breakers, transformers, switchboards, panel boards, metering products, and busway products; lighting and controls, including lamps, fixtures, ballasts, and lighting control products; and motor control devices, drives, surge and power protection, relays, timers, pushbuttons, operator interfaces, switches, sensors, and interconnects. Further, it provides value added services in the areas of construction, e-business, energy, engineering services, green and sustainability, production support, safety and security, supply chain optimization, training, and working capital. The company serves industrial and commercial businesses, contractors, governmental agencies, institutions, telecommunications providers, and utilities. It operates in North America and internationally. WESCO International, Inc. was founded in 1922 and is headquartered in Pittsburgh, Pennsylvania.
Advisors' Opinion:- [By Ben Levisohn]
Citigroup’s Deane Dray and team took a long hard look at the U.S. economy and the their ratings on diversified industrial like United Technologies (UTX), Honeywell (HON), Tyco (TYC) and Wesco International (WCC) and decided it was time to makes some changes.
- [By Seth Jayson]
WESCO International (NYSE: WCC ) reported earnings on April 18. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), WESCO International met expectations on revenues and missed estimates on earnings per share.
No comments:
Post a Comment